Third Death In Audentes’ XLMTM Gene Therapy Trial
But Companies Remain 'Committed'
Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.
Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.